Immune checkpoint blockade (ICB) therapies have achieved significant breakthroughs in cancer treatment over the past decade. However, ICB is largely ineffective in desert-type gastric cancer due to intrinsic tumor heterogeneity and a highly immunosuppressive tumor microenvironment (TME). Transforming tumors from an immunosuppressive state to an immunostimulatory state is a potential approach to enhance ICB response. In this study, we developed a chromosomal instability–subtype gastric cancer mouse model with an immunoactive TME and a stem cell–originated mouse-derived allograft model with an immunosuppressed TME to investigate mechanisms regulating the tumor immunophenotype and uncover therapeutic strategies to remodel the TME. Blocking β-catenin signaling attenuated the immunochemotherapeutic resistance of mouse-derived allograft tumors. The tyrosine kinase inhibitor apatinib reprogrammed the TME by increasing CD8+ T-cell and IGHA+ plasma cell infiltration and decreasing M2 macrophages, but apatinib also induced PD-L1 and CD80 expression in both human and mouse desert–type tumors. Oxaliplatin decreased the apatinib-induced expression of immune checkpoints and enhanced the antitumor efficacy of immunotherapy. A prospective clinical trial (NCT04195828) demonstrated that a neoadjuvant regimen of apatinib plus ICB and chemotherapy was effective in patients with desert-type gastric cancer. Collectively, these findings identify potential drug targets for immune desert–type gastric cancer driven by β-catenin signaling. Significance: Apatinib combined with oxaliplatin reprograms the tumor immune microenvironment in desert-type gastric cancer, enhancing the efficacy of immune checkpoint blockade and paving the way for optimized combination immunotherapeutic strategies.
Gastric mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) are aggressive malignancies that exhibit complex cellular heterogeneity driven by the dual lineages. The dismal patient survival rates highlight the need to elucidate the cellular origin of gastric MiNENs and the key regulatory mechanisms to develop improved treatment strategies. Here, we identified a gastric POU2F3+epithelial population as a potential cell of origin for gastric MiNENs. Lineage tracing and single-cell RNA sequencing further identified that POU2F3+ cells include three distinct subpopulations with divergent differentiation trajectories: progenitor cells (SOX2+SOX9+), tuft cells (POU2F3+DCLK1+), and neuroendocrine cells (SYP+CHGA+). Combined Rb1/Trp53 deletion and MYC overexpression in POU2F3+ epithelial cells (Pou2f3-CreERT; Rb1fl/fl; Trp53fl/fl; LSL-MycT58A) led to the rapid development of gastric MiNENs containing both neuroendocrine and non-neuroendocrine lesions, recapitulating human gastric MiNENs pathology. Transcription factor activity analysis and spatial transcriptomics revealed SOX2 and SOX9 as critical regulators driving subpopulation specification, with SOX2 and SOX9 being enriched in dysplasia and adenocarcinoma, respectively. Bulk RNA sequencing further showed increased expression of CXCL5 in gastric MiNENs, and inhibition of CXCL5 reduced the growth of tumor organoids and xenografts in mouse models. Together these findings offer a physiologically relevant model for studying gastric MiNENs and identify CXCL5 as a potential therapeutic target for this heterogeneous cancer.
Supplementary Table S3 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Supplementary Table S4 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy